期刊文献+

腺苷对人胃癌MGC-803细胞增殖与凋亡的影响 被引量:3

Effects of adenosine on proliferation and apoptosis in human gastric cancer cell line MGC-803
下载PDF
导出
摘要 目的 观察腺苷(adenosine)对人胃癌MGC-803细胞的增殖、凋亡的影响。方法 CCK-8法检测不同浓度腺苷(0.01-10 mmol/L)对胃癌MGC-803细胞增殖的影响。流式细胞仪检测腺苷(0.25、0.5、1 mmol/L)对细胞凋亡的影响。Western blot检测腺苷处理后细胞内凋亡相关蛋白和内质网应激相关蛋白的表达量。结果 腺苷能抑制胃癌MGC-803细胞的活力,并且呈现浓度和时间依赖性(P〈0.05)。腺苷(0.25、0.5、1 mmol/L)处理24 h后,细胞的总凋亡率显著升高(P〈0.01)。腺苷可以引起凋亡相关蛋白Caspase-3活化片段的蛋白表达量上调(P〈0.01)。腺苷能诱导内质网应激(ERS)相关蛋白Caspase-4活化片段、p-JNK、CHOP、GRP78的表达量上调(P〈0.05)。结论 腺苷可以抑制胃癌MGC-803细胞的增殖,并且促进凋亡,而内质网应激可能参与了腺苷引起的凋亡。 Objective To explore the influence of adenosine on proliferation and apoptosis in human gastric cancer cell line MGC-803. Methods MGC-803 cells were treated with different concentrations of adenosine (0.01 - 10 mmol/L), and CCK-8 was used to observe cell proliferation. Flow cytometry (FCM) was used to analyze cells apoptosis after treatment of adenosine. Apoptosis protein Caspase-3 and endoplasmic reticulum stress (ERS) related proteins (casepase-4, p-JNK, CHOP, GRP78) were detected by Western blotting. Results Adenosine significantly inhibited the MGC-803 cells viability in a concentration- and time-dependent manner (P 〈 0.05 ). After treatment with adenosine (0.25, 0.5, 1 retool/L) for 24 h, total apoptosis rate of cells significantly increased (P 〈0.01 ). Expression of cleaved Caspase-3 was significantly up-regulated after treatment with adenosine (P 〈 0.01 ). ERS related proteins ( casepase-4, p-JNK, CHOP, GRP78) were significantly up-regulated in adenosine treated group (P 〈 0.05 ). Conclusion Adenosine can significantly suppress proliferation and induce apoptosis in MGC-803 cells, while endoplasmic reticulum stress is involved in adenosine-induced apoptosis.
出处 《实用临床医药杂志》 CAS 2016年第13期44-47,55,共5页 Journal of Clinical Medicine in Practice
关键词 胃癌 腺苷 增殖 凋亡 内质网应激 gastric carcinoma adenosine proliferation apoptosis endoplasmic reticulum stress
  • 相关文献

参考文献17

  • 1Global Burden of Disease Cancer C,Fitzmaurice C,Dicker D,et al.The Global Burden of Cancer 2013[J].JAMA oncology,2015,1(4):505-527.
  • 2Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].International journal of cancer Journal international du cancer,2015,136(5):E359-386.
  • 3Wei Deng,Qi-Wei Wang,Xiao-Tian Zhang,Ming Lu,Jie Li,Yan Li,Ji-Fang Gong,Jun Zhou,Zhi-Hao Lu,Lin Shen.Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer[J].World Journal of Gastroenterology,2014,20(12):3356-3363. 被引量:2
  • 4Yu S,Hou D,Chen P,et al.Adenosine induces apoptosis through TNFR1/RIPK1/P38 axis in colon cancer cells[J].Biochemical and biophysical research communications,2015,460(3):759-765.
  • 5Fredholm B B.Adenosine-a physiological or pathophysiological agent?[J].Journal of molecular medicine,2014,92(3):201-206.
  • 6Yang D,Song J,Wu L,et al.Induction of senescence by adenosine suppressing the growth of lung cancer cells[J].Biochemical and biophysical research communications,2013,440(1):62-67.
  • 7Ma Y,Zhang J,Zhang Q,et al.Adenosine induces apoptosis in human liver cancer cells through ROS production and mitochondrial dysfunction[J].Biochemical and biophysical research communications,2014,448(1):8-14.
  • 8Shirali S,Aghaei M,Shabani M,et al.Adenosine induces cell cycle arrest and apoptosis via cyclin D1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3[J].Tumour biology:the journal of the International Society for Oncodevelopmental Biology and Medicine,2013,34(2):1085-1095.
  • 9Tsuchiya A,Kanno T,Saito M,et al.Intracellularly transported adenosine induces apoptosis in[corrected]MCF-7 human breast cancer cells by accumulating AMID in the nucleus[J].Cancer letters,2012,321(1):65-72.
  • 10Kim H S,Kim J H,Kim J W,et al.Chemotherapy in Elderly Patients with Gastric Cancer[J].Journal of Cancer,2016,7(1):88-94.

二级参考文献35

  • 1Ilfet Songun,Hein Putter,Elma Meershoek-Klein Kranenbarg,Mitsuru Sasako,Cornelis JH van de Velde.Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncology . 2010 (5)
  • 2Network NCC. NCCN Clinical Practice Guidelines in Oncology:Gastric Cancer, 2015.
  • 3Snyder RA, Penson DF, Ni S, Koyama T, Merchant NB. Trends inthe use of evidence-based therapy for resectable gastric cancer. JSurg Oncol 2014; 110: 285-290 [PMID: 24891231 DOI: 10.1002/jso.23635].
  • 4Hallissey MT, Dunn JA, Ward LC, Allum WH. The secondBritish Stomach Cancer Group trial of adjuvant radiotherapy orchemotherapy in resectable gastric cancer: five-year follow-up.Lancet 1994; 343: 1309-1312 [PMID: 7910321].
  • 5Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, EstesNC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL,Jessup JM, Martenson JA. Chemoradiotherapy after surgerycompared with surgery alone for adenocarcinoma of the stomachor gastroesophageal junction. N Engl J Med 2001; 345: 725-730[PMID: 11547741 DOI: 10.1056/NEJMoa010187].
  • 6Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC,Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM,Stemmermann GN, Blanke CD, Macdonald JS. Updated analysisof SWOG-directed intergroup study 0116: a phase III trial ofadjuvant radiochemotherapy versus observation after curativegastric cancer resection. J Clin Oncol 2012; 30: 2327-2333 [PMID:22585691 DOI: 10.1200/JCO.2011.36.7136].
  • 7Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY,Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, JungSH, Park CK, Kim KM, Kang WK. Phase III trial comparingcapecitabine plus cisplatin versus capecitabine plus cisplatinwith concurrent capecitabine radiotherapy in completely resectedgastric cancer with D2 lymph node dissection: the ARTIST trial. JClin Oncol 2012; 30: 268-273 [PMID: 22184384 DOI: 10.1200/JCO.2011.39.1953].
  • 8Dikken JL, van Sandick JW, Maurits Swellengrebel HA, LindPA, Putter H, Jansen EP, Boot H, van Grieken NC, van de VeldeCJ, Verheij M, Cats A. Neo-adjuvant chemotherapy followed bysurgery and chemotherapy or by surgery and chemoradiotherapyfor patients with resectable gastric cancer (CRITICS). BMC Cancer2011; 11: 329 [PMID: 21810227 DOI: 10.1186/1471-2407-11-329].
  • 9Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, LeeKW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS,Button P, Sirzén F, Noh SH. Adjuvant capecitabine and oxaliplatinfor gastric cancer after D2 gastrectomy (CLASSIC): a phase 3open-label, randomised controlled trial. Lancet 2012; 379: 315-321[PMID: 22226517 DOI: 10.1016/S0140-6736(11)61873-4].
  • 10Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M,Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, ImamuraH, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvantchemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.N Engl J Med 2007; 357: 1810-1820 [PMID: 17978289 DOI:10.1056/NEJMoa072252].

共引文献21

同被引文献30

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部